2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-153554
    NLRP3-IN-18 2769040-06-2 98.06%
    NLRP3-IN-18 (compound 13) is a potent NLRP3 inhibitor with an IC50 value of ≤1.0 µM.
    NLRP3-IN-18
  • HY-153579
    Anti-inflammatory agent 42 877468-30-9 98.0%
    Anti-inflammatory agent 42 (Compound 10j) is an anti-inflammatory agent. Anti-inflammatory agent 42 shows excellent inhibition on the expression of TNF-α and IL-6 in LPS (HY-D1056)-stimulated macrophages.
    Anti-inflammatory agent 42
  • HY-153612
    MMV009085 298217-59-1 98.68%
    MMV009085 is a potent PfHT1 (Plasmodium falciparum hexose transporter)-specific inhibitor and a potential anti-malarial agent . MMV009085 is also a human glucose transporter inhibitor, it has high potency in inhibiting both glucose uptake (IC50: 2.6 μM in glucose uptake assay) and growth of the parasites (EC50: 1.23±0.04 μM against 3D7).
    MMV009085
  • HY-15382A
    (S)-FTY720-phosphonate 1142015-10-8 99.91%
    FTY720 (S)-Phosphate is an agonist of S1P receptor 1 (S1PR1), used in the research of acute inflammatory diseases such as acute lung injury.
    (S)-FTY720-phosphonate
  • HY-153840
    ODN INH 18 1934318-43-0
    ODN INH-18 is a linear 24-mer class B INH-ODN in which the 5' INH-ODN 4084-F sequence was followed by a random stretch of 12 nucleotides lacking the ability to form significant secondary structures. ODN INH-18 showes inhibitory potency for TLR9 ligand-induced IFN-α production.
    ODN INH 18
  • HY-153969
    URAT1 inhibitor 6 2244807-49-4 99.01%
    URAT1 inhibitor 6 (Compound 1h) is a potent URAT1 inhibitor (IC50: 35 nM for hURAT1). URAT1 inhibitor 6 is 200- and 8-fold more potent than parent Lesinurad (HY-15258) and Benzbromarone (HY-B1135). URAT1 inhibitor 6 can be used for research of inflammation.
    URAT1 inhibitor 6
  • HY-153972
    URAT1&XO inhibitor 2 1239488-96-0 98.69%
    URAT1&XO inhibitor 2 (Compound BDEO) is a dual inhibitor of xanthine oxidase and URAT1, with IC50 of 3.3 μM for xanthine oxidase. URAT1&XO inhibitor 2 blocks uptake of uric acid in HEK293 cells expressing URAT1, with a Ki value of 0.145 μM. URAT1&XO inhibitor 2 decreases serum urate level and uric acid excretion in hyperuricemic mice. URAT1&XO inhibitor 2 can be used for research of hyperuricemia.
    URAT1&XO inhibitor 2
  • HY-15427A
    GDC-0834 Racemate 1133432-46-8 98.04%
    GDC-0834 Racemate is the racemic form of GDC-0834 (HY-15427). GDC-0834 is an orally active selective, potent, and reversible BTK inhibitor with an IC50 of 5.9 nM. GDC-0834 demonstrates pBTK-Tyr223 inhibition in mice and rats. GDC-0834 can be used for research of rheumatoid arthritis (RA).
    GDC-0834 Racemate
  • HY-154438
    RDR 02308 4155-82-2 98.0%
    RDR 02308 is a TLR4-MyD88 binding inhibitor that inhibits full-length β-lactamase.
    RDR 02308
  • HY-154821
    DRI-C21041 2101765-78-8 98%
    DRI-C21041 is a CD40/CD40L interaction inhibitor, with an IC50 of 0.31 μM. DRI-C21041 inhibits the immune response induced by alloantigen.
    DRI-C21041
  • HY-154860
    PTD10 2642231-19-2
    PTD10 is a selective and potent BTK PROTAC degrader (DC50 = 0.5 nM, KD = 2.28 nM). PTD10 can recruit cereblon (CRBN) E3 ligase and form a ternary complex with BTK, thereby mediating the ubiquitination and proteasome-dependent degradation of BTK. PTD10 inhibits cancer cells proliferation, and induces cell apoptosis via activation of the caspase-dependent pathway and mitochondrial pathway. PTD10 potently inhibits the BCR, AKT and NF-κB signaling pathway. PTD10 can be used for researches of B-cell malignancies and autoimmune disease.
    PTD10
  • HY-155525
    Anti-NASH agent 1 2409685-41-0 98.49%
    Anti-NASH agent 1 (compound 3d)，a derivative of Elafibranor (HY-16737)，is a potent agonist of PPAR-α/δ，targeting to nonalcoholic steatohepatitis (NASH). Anti-NASH agent 1 (3-10 mg/kg; 4 weeks) improves hyperlipidemia，liver fat degeneration and liver inflammation in Methionine-choline deficiency (MCD) induced NASH mice model. Anti-NASH agent 1 shows low liver toxicity and potent liver protection effect.
    Anti-NASH agent 1
  • HY-155978
    RDN2150 2839429-51-3 98%
    RDN2150 is a ZAP-70 inhibitor with an IC50 of 14.6 nM, and it exhibits selectivity for Syk over other kinases. RDN2150 inhibits signal transduction and activation of T cells/CAR-T cells, reduces the phosphorylation level of Erk1/2, suppresses the induction of CD69 and IL-2, and downregulates phosphotyrosine signaling pathways including hnRNP sites in T cells. RDN2150 can be used for psoriasis-related research.
    RDN2150
  • HY-156023
    SIRT1 activator 2 863589-52-0 99.28%
    SIRT1 activator 2 is a SIRT1 activator with an ED50 value <5 μM. SIRT1 activator 2 modulates SIRT1 deacetylase activity. SIRT1 activator 2 can be used for aging research.
    SIRT1 activator 2
  • HY-156034
    JT001 2238819-65-1 98%
    JT001 (NLRP3-IN-19) is a potent, specific and orally active inhibitor of NLRP3. JT001 can inhibit NLRP3 inflammasome assembly, resulting in the inhibition of cytokine release and the prevention of pyroptosis. JT001 can be used for the research of nonalcoholic steatohepatitis and liver fibrosis.
    JT001
  • HY-15652A
    Freselestat quarterhydrate ≥99.0%
    Freselestat quarterhydrate (ONO-6818 quarterhydrate) is a potent and orally active neutrophil elastase inhibitor with a Ki of 12.2 nM. Freselestat quarterhydrate is >100-fold less-active against other proteases such as trypsin, protein-ase 3, pancreatic elastase, plasmin, thrombin, collagenase, cathepsin G, and murine macrophage elastase. Freselestat quarterhydrate has a potent anti-inflammatory activity.
    Freselestat quarterhydrate
  • HY-15656S
    Ceritinib-d7 1632484-77-5 ≥98.0%
    Ceritinib (LDK378)-d7 is a deuterium labeled Ceritinib (HY-15656). Ceritinib is a selective, orally bioavailable and ATP-competitive ALK tyrosine kinase inhibitor. Ceritinib is a selective, orally bioavailable, and ATP-competitive ALK tyrosine kinase inhibitor with an IC50 of 200 pM. Ceritinib also inhibits IGF-1R, InsR, and STK22D with IC50 values of 8, 7, and 23 nM, respectively. Ceritinib shows great antitumor potency.
    Ceritinib-d7
  • HY-156612
    Friluglanstat 1422203-86-8 98%
    Friluglanstat is a prostaglandin E synthase (mPGES-1) inhibitor, with anti-inflammatory activity.
    Friluglanstat
  • HY-156616
    VC1052 370108-98-8 99.72%
    VC1052 is a dialkoxypropylammonium-based material and is the core cationic lipid component of the cationic lipid adjuvant Vaxfectin (HY-142998). Vaxfectin consists of VC1052 and lipid DPyPE (HY-112766) in a 1:1 molar ratio. Vaxfectin can be used as a vaccine adjuvant for the preparation of plasmid DNA and protein vaccines.
    VC1052
  • HY-156667
    H4R antagonist 3 1003091-20-0
    H4R antagonist 3 (Example 8) is a histamine-4 and -1 receptor antagonist with EC50 of ≤10 mM. H4R antagonist 3 can be used for the research of prevention of inflammatory, autoimmune, allergic, and ocular diseases.
    H4R antagonist 3
Cat. No. Product Name / Synonyms Application Reactivity